Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (NYSE: ALC) announced the U.S. launch of Clareon TruPlus, an enhanced-design monofocal and toric IOL that extends depth of focus while preserving high-quality distance vision.
Bench data show a 3.5-letter simulated acuity gain at -1.5 D versus Clareon Monofocal, higher distance image quality versus TECNIS Eyhance, and lower glare/halo on bench comparisons. TruPlus will roll out to additional markets later in 2026.
Alcon (SIX/NYSE: ALC) will hold its 2026 Annual General Meeting on April 30, 2026, its fourth in-person AGM since becoming independent. The Board proposes electing R. Scott Herren as an independent director and recommends a proposed gross cash dividend of CHF 0.28 per share.
If approved, the ex-dividend dates are expected to be May 5, 2026 (SIX SIS) and May 6, 2026 (DTC), with a record date of May 6, 2026 and payout in Switzerland around May 7, 2026. A 35% Swiss withholding tax applies.
Alcon (SIX/NYSE: ALC) and LENSAR (NASDAQ: LNSR) agreed to terminate their previously announced merger. The companies said the nearly one-year regulatory review and the FTC's opposition made the transaction unattractive to pursue.
Alcon cited delay and associated costs and reaffirmed its commitment to advancing cataract surgery technologies.
Alcon (NYSE:ALC) announced it has surpassed 175 million intraocular lens (IOL) implants worldwide as of January 2026, including > 6 million presbyopia‑correcting IOLs (PCIOLs).
Key products: PanOptix (over 4 million implants), Vivity (over 2 million), and newly launched Clareon PanOptix Pro with 94% light utilization and reduced scatter.
Alcon (NYSE: ALC) reported fourth-quarter 2025 net sales of $2.7B, up 9% reported and 7% constant currency, and full-year sales of $10.3B, up 5% reported. Q4 diluted EPS was $0.44 (core diluted EPS $0.78). Operating income and margins declined amid launch investments and acquisition costs. Full-year free cash flow was $1.7B and the company returned $848M to shareholders.
Alcon (NYSE: ALC) launched TOTAL30 Multifocal for Astigmatism, the first monthly multifocal toric contact lens with Water Gradient Technology, now commercially available in the U.S. The lens reportedly delivers near 8/10 end-of-day comfort on day 30, 97% first-lens fit success, and fits nearly 90% of astigmatic presbyopes.
Available powers span +6.00 to -10.00 D with three ADDs and cylinder options 0.75–1.75; limited international rollout planned for 2026.
Alcon (NYSE: ALC) launched PRECISION7 in Canada on February 2, 2026, a one-week replacement sphere and toric contact lens featuring the world’s first ACTIV-FLO System that the company says continuously moisturizes the lens surface for seven days and delivers 16 hours of comfort and precise vision.
PRECISION7 joins Alcon’s WaterInnovations portfolio as a weekly alternative when daily disposables are not chosen for cost reasons, and will be commercially available in Canada starting February 2026.
Alcon (NYSE:ALC) announced completion of its $750 million share repurchase program that began on April 1, 2025. In aggregate, 9,301,877 registered shares were bought on the SIX Swiss Exchange, representing 1.9% of current share capital. The total buyback volume was CHF 602 million (USD 750 million). Acquired registered shares will be held in treasury and are intended to offset dilution from registered shares vesting under Alcon's equity-based incentive plans.
The program reduces outstanding shares and targets dilution from employee equity awards while using CHF cash resources.
Alcon (SIX/NYSE: ALC) announced on January 7, 2026 that it has terminated its definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) that was announced on August 5, 2025. The company said it remained disciplined on price and risk and that its refractive strategy is unchanged, with a continued focus on its wavelight® plus offering for LASIK.
Alcon also said it will continue global launches of more than 10 major products across surgical and vision care this year and reiterated forward-looking caution about uncertainties and risks.
Broadwood Partners, which owns 30.2% of STAAR common stock (NASDAQ: STAA), thanked shareholders after preliminary results from the January 6, 2026 Special Meeting showed a decisive vote to reject the proposed acquisition of STAAR by Alcon (NYSE: ALC). Broadwood reiterated confidence in STAAR’s standalone prospects, citing leading technology, a strong financial position, large market opportunities, and a path to margin expansion.
Broadwood said it is ready to engage with the board and fellow shareholders to implement changes aimed at improving oversight and execution to help STAAR pursue growth and profitability as an independent company.